PIK3CA and breast cancer: In this context, adding a PI3K inhibitor to anti-ER therapy may be an attractive treatment option for women with advanced HR+ BC that becomes resistant to endocrine therapy, according to findings from the phase III BELLE-2 trial [36]. In a secondary analysis of the BOLERO-2 study, a large study providing overall survival data with respect to ESR1 mutations has been conducted [37].